People, knowledge, communication, and capitalism were front and center as authorities on innovation sought to shed light on ways to
speed up the development of new medical treatments from discoveries in
the lab.
The speakers, who drew on lessons from the computer industry and
from past startup ventures, were part of the “Harvard Medical School
Dean’s Symposium on Clinical and Translational Research,” sponsored by
Harvard Catalyst: The Harvard Clinical and Translational Science
Center.
The event presented three separate symposia over two days. The
opening event, “Challenges to Successful Innovation and Translation,”
was held at Harvard Business School’s
Spangler Auditorium. The remaining two events, “Thought, Emotion and
the Brain” and “Medical Nanotechnology: Small Is Big,” were held at Harvard Medical School and at the Harvard-affiliated
Schepens Eye Research Institute.
Topics covered ranged from microfluidics and nanoelectronics to the
search for autism genes and regulating the brain. Yochai
Benkler, the Berkman Professor for Entrepreneurial Legal Studies at
Harvard Law School, said that knowledge resides mainly in individuals
and that innovation depends on getting people to communicate.
Information flow, however, tends to be blocked by efforts to control
that information, for profit or other reasons.
Benkler compared how Massachusetts and California’s Silicon Valley
each weathered the computer transition to personal computing and the
Internet. While Massachusetts companies suffered, Silicon Valley
companies such as Apple and Google flourished. The reason, he said, is
that there was a culture of sharing information in Silicon Valley and
people regularly switched jobs. The legal underpinnings in California
were more conducive to information flow, he said, since no-compete
clauses were rarely enforced.
“Knowledge resides in people. A lot of knowledge is passive and not
something that can be passed onto the next person [in a job],” Benkler
said. “Innovation emerges from connecting people’s minds.”
Another example Benkler used was the open-source software movement,
which requires collaboration from people who don’t work together to
constantly improve software. Though it may not be competitive to share
information outside one’s company, the movement recognizes a truth
about technology that also applies to other fields such as health care.
“Knowledge resides in people, not all of whom work in your project or company,” Benkler said.
One problem with the current model of medical research, Benkler
said, is that it doesn’t recognize or reward someone who may be
particularly collaborative, bringing together different people in
different departments, even though those connections may be essential
for innovation.
“Ensuring flow may mean releasing control and that may mean changing
some of the basic aspects of the systems we have,” Benkler said.
Srikant Datar, Dickinson Professor of Accounting, senior associate
dean, and director of research at Harvard Business School, said that
innovation often comes packaged with a measure of distance from a
problem. He cited the success of an English clockmaker in determining
longitude, a problem that had defied scientists and sailors alike.
George Whitesides, the Flowers University Professor, drew on his own
experience with startup companies to offer more practical advice about
taking scientific discoveries to market.
Whitesides said that commercialization of an advance is important
because without a company to bring an advance to market, it is useless
to patients and other potential customers. That happens through
capitalism, often through venture capitalism.
Whitesides cautioned that though venture capitalism can bring money
to a project, it also can lead to a loss of control and so should be
used sparingly. He counseled that one should hire good people and pay
them well, but keep a sharp eye on expenses.
From a commercial standpoint, he said, a risky project that might
not work is bad, as is one that will take a long time to come to
market, since each will raise costs. He advised researchers to “finish
the science” before starting a company, because research comes along on
its own schedule. In addition, he urged researchers to learn basic
accounting before embarking on any business venture.
“That way you won’t appear as an object of prey rather than as a partner,” Whitesides said.